The nation of Zimbabwe has turned down a major US health deal worth $367m (272 million pounds) over five years over Washington's demand for confidential information.
This move became public after a government memo from December was disclosed, which showed Head of State Emmerson Mnangagwa believed the arrangement was "lopsided".
An official spokesman later stated that the US was seeking genetic material for scientific study and commercial purposes but refused to guarantee the resulting advantages from future treatments.
"We are forced to start the challenging and unfortunate process of ending our health aid in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont in a statement.
Her embassy noted the United States had furnished over $1.9bn in health funding to Zimbabwe over the last two decades.
A physicians' group in Zimbabwe has urged further talks to reach a agreement agreeable to all parties so the country's vital HIV treatment initiative can proceed.
Wider Implications
This rejection comes after a comparable situation in Kenya, where a court halted a related health funding agreement following legal challenges were filed about the safety of citizens' medical information.
Since returning to the presidency recently, US President Donald Trump has slashed overseas assistance and closed the US Agency for International Development (USAID).
USAID had overseen aid for the US government, but Trump argued its expenditure was "inefficient" and his government was pursuing government-to-government deals to enhance transparency and accountability.
Based on statements, 16 nations in Africa have so far signed similar agreements, constituting over $18.3bn of fresh investment.
Details of the Rejected Agreement
The money for Zimbabwe was intended to gone towards "HIV/Aids treatment and prevention, TB, malaria, maternal and child health, and preparing for epidemics".
"We believe this partnership might have yielded extraordinary advantages for the people of Zimbabwe, especially the 1.2 million men, women and children presently receiving antiretroviral therapy via American-funded programmes," the Ambassador added.
However, government spokesperson Nick Mangwana argued the proposed deal was "asymmetrical".
"Zimbabwe was being asked to share its genetic material and health information for a long time, without any corresponding promise of access to any scientific breakthroughs – such as vaccines, diagnostics, or treatments – that could be developed from that shared data," he stated.
"Effectively, our nation would supply the basic resources for medical research without any assurance that the resulting innovations would be available to our people if a future health crisis arise."
Sovereignty and Global Health
Mangwana further pointed out that the US's withdrawal from the World Health Organization (WHO) and its push of bilateral deals were disrupting frameworks previously established via the international health agency.
The spokesperson gave as an example its Pathogen Access and Benefit Sharing framework designed to manage future pandemics.
"This framework is designed to guarantee that when a country provides its information, the benefits – such as medicines and cures – are distributed fairly, not commercialised solely by those with the funds to develop them."
Zimbabwe's reservations over the US deal "should not be misconstrued as opposition to America," Mangwana stressed.
"We welcome further dialogue with our American counterparts on how subsequent collaboration might be arranged in a way that respects the independence and interests of both nations."
Medical Community Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) expressed it acknowledged the official position, but recommended that negotiations need to persist considering a large portion of the nation's HIV programmes relied on external financing.
"In cases where specific concerns arise, including those relating to data governance or agreement terms, these can frequently be resolved through technical clarification and negotiated safeguards," the group commented.
The halted deal highlights the ongoing tensions between accepting crucial international aid and safeguarding national sovereignty in an ever more interconnected world.